ProLynx, 455 Mission Bay Blvd. South, Suite 341, San Francisco, CA 94158, United States.
ProLynx, 455 Mission Bay Blvd. South, Suite 341, San Francisco, CA 94158, United States.
J Control Release. 2018 May 28;278:74-79. doi: 10.1016/j.jconrel.2018.03.021. Epub 2018 Mar 22.
We have developed a chemically-controlled drug delivery system in which a drug is covalently attached via a carbamate to hydrogel microspheres using a β-eliminative linker; rate-determining proton removal from a CH bond adjacent to an electron withdrawing group results in a β-elimination to cleave the carbamate and release the drug. After subcutaneous injection of the hydrogel-drug conjugate, the drug is slowly released into the systemic circulation and acquires an elimination t that matches the t of linker cleavage. A similar β-eliminative linker with a slower cleavage rate is installed into crosslinks of the polymer to trigger gel degradation after drug release. We have now prepared β-eliminative linkers that contain deuterium in place of the hydrogen whose removal initiates cleavage. In vitro model systems of drug release and degelation show large primary deuterium kinetic isotope effects of k/k ~ 2.5 to 3.5. Using a deuterated linker to attach the peptide octreotide to hydrogel-microspheres, the in vivo t of the drug was increased from ~1.5 to 4.5 weeks in the rat. Similarly, the in vivo time to biodegradation of hydrogels with deuterium-containing crosslinks could be extended ~2.5-fold compared to hydrogen-containing counterparts. Thus, the use of primary deuterium kinetic isotope effects in a single platform technology can control rates of β-elimination reactions in drug release and polymer biodegradation rates.
我们开发了一种化学控制的药物传递系统,其中药物通过氨基甲酸酯键共价连接到水凝胶微球上,使用β-消除性连接子;相邻于吸电子基团的 CH 键的质子的离去决定了β-消除,从而切断氨基甲酸酯键并释放药物。在皮下注射水凝胶-药物缀合物后,药物缓慢释放到体循环中,并获得与连接子裂解相匹配的消除半衰期 t。将一种具有较慢裂解速率的类似β-消除连接子安装到聚合物交联中,在药物释放后触发凝胶降解。我们现在已经制备了含有氘取代氢的β-消除连接子,其去除引发裂解。药物释放和凝胶降解的体外模型系统显示出较大的初级氘动力学同位素效应 k/k ~ 2.5 至 3.5。通过将肽奥曲肽用氘取代的连接子连接到水凝胶微球上,药物在大鼠体内的 t 从约 1.5 增加到 4.5 周。同样,与含有氢的交联相比,含有氘的交联的水凝胶的体内生物降解时间可以延长约 2.5 倍。因此,在单个平台技术中使用初级氘动力学同位素效应可以控制药物释放和聚合物生物降解速率中的β-消除反应速率。